| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T745 |
0-4 |
Sentence |
denotes |
3.4. |
| T746 |
6-118 |
Sentence |
denotes |
Bioavailability radar and score as parameters for analysis of pharmacokinetic properties of WS phytoconstituents |
| T747 |
119-243 |
Sentence |
denotes |
Pharmacokinetics and pharmacodynamics are two interlinked terms in drug development having a mutual influence on each other. |
| T748 |
244-356 |
Sentence |
denotes |
Bioavailability radar offers a first glimpse into the pharmaceutical properties of a prospective drug candidate. |
| T749 |
357-671 |
Sentence |
denotes |
By convention, the pink area represents the optimal biological range for each physiochemical property including lipophilicity (XLOGP3 range 0.7–5.0), size (MW range 150–500), polarity (TPSA range 20–130 Å2), solubility (log S ≤ 6), saturation (fraction of carbons in sp3 hybridization ≤0.25), and flexibility (≤9). |
| T750 |
672-876 |
Sentence |
denotes |
The Abbot Bioavailability Score62 is identical, but attempts to determine whether a compound is likely to have oral bioavailability score of at least 10% in rats and/or Caco-2 permeability (Martin, 2005). |
| T751 |
877-1053 |
Sentence |
denotes |
As is evident from Figure 2A and B, all withanolides from WS exhibited a significant bioavailability radar and score as comparable to the standard reference FDA-approved drugs. |
| T752 |
1054-1257 |
Sentence |
denotes |
Figure 2. (A) Bioavailability radar and score prediction of WS phytoconstituents using SwissADME. (B) Bioavailability radar and score prediction of FDA–approved reference standard drugs using SwissADME. |
